Sign in

Private company

Tesaro

Logo: Tesaro, CC BY-SA 4.0, via Wikimedia Commons5

American pharmaceutical company

Tesaro Inc. is a pharmaceutical company based in Waltham, Massachusetts. They focus on drug development for cancer.3 Wikipedia text CC BY-SA 4.0

Last updated Oct 21, 2026.

Overview

2010Founded1
  • IndustryPharmaceutical Preparations1
  • HeadquartersWaltham1
  • Websitewww.tesarobio.com
  • Incorporated inDE6
  • Business address1000 Winter Street, Suite 3300, Waltham, Ma 024516
  • Filer categoryLarge accelerated filer6
  • Legal formDomestic Business Corporation4
  • LEI2549002X18IVK5P436794
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered address1000 Winter Street, 02451 Waltham, United States4
  • Registered withCorporations Division (Secretary of the Commonwealth's Office), 2722496874

See how the biggest companies compare on our leaderboards

Tesaro Inc. is a pharmaceutical company based in Waltham, Massachusetts. They focus on drug development for cancer.3

What it owns

What Tesaro reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$15.6M8 Dec 31, 2017$9.3M8 Dec 31, 2016+69.0%
Accumulated depreciation$6.0M8 Dec 31, 2017$2.6M8 Dec 31, 2016+129.0%
Property and equipment, net$9.7M8 Dec 31, 2017$6.6M8 Dec 31, 2016+45.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$643.1M8 Dec 31, 2017$785.9M8 Dec 31, 2016−18.2%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$56.4M8 Dec 31, 2017$12.9M8 Dec 31, 2016+337.9%
Finite-lived intangibles, gross$64.7M8 Dec 31, 2017$15.0M8 Dec 31, 2016+331.1%
Accumulated amortization$8.3M8 Dec 31, 2017$2.1M8 Dec 31, 2016+290.1%
Finite-lived intangibles, net$56.4M8 Dec 31, 2017$12.9M8 Dec 31, 2016+337.9%

Inventory

ItemLatestA year beforeChange
Raw materials$17.9M8 Dec 31, 2017$13.3M8 Dec 31, 2016+34.8%
Work in process$38.6M8 Dec 31, 2017$584.0K8 Dec 31, 2016+6514.6%
Finished goods$1.4M8 Dec 31, 2017$853.0K8 Dec 31, 2016+68.1%

The story

Tesaro was founded in 2010. The company's first commercial product, Varubi, was approved by the FDA in October 2015. As of 2016, the company had 286 full-time employees, 59 of whom had a PhD or MD. The company's product Niraparib was granted priority review and was given a target action date of June 2017 by the FDA. In March 2017, Tesaro won approval for its drug Zejula to treat ovarian cancer. On May 31, 2017, it was reported that Tesaro Inc. was exploring a sale. On December 3, 2018, GSK announced it would acquire the company for $5.1 billion, and the deal was completed on January 22, 2019.

From Wikipedia’s article on Tesaro, shared under CC BY-SA 4.0.7

Leadership

Who has led Tesaro, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Leon O. Moulder Jr.2012–2019
  2. Jack A. Khattar2016

President

  1. Mary Lynne Hedley2013–2019
  2. Jack A. Khattar2016

Chief financial officer

  1. Richard J. Rodgers2012–2013
  2. Timothy R. Pearson2014–2019

Chief operating officer

  1. Mary Lynne Hedley2015–2019
201520202025
Board members and other officers (20)

Products and brands

  • rolapitant

Listed on Wikidata.1

Rolapitant – intravenous form in phase III clinical trials for use in chemotherapy-induced nausea and vomiting

Niraparib – PARP inhibitor in clinical trials for breast and ovarian cancer.

TSR-042

TSR-022

Read the full text

Dostarlimab – In February 2023, the FDA approved dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adults with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.

From Wikipedia’s article on Tesaro, shared under CC BY-SA 4.0.7

Timeline

  1. Mar 30, 2016New chief executive Jack A. Khattar becomes CEO9
  2. Jun 27, 2012New chief executive Leon O. Moulder Jr. becomes CEO10
  3. 2010Founded Founded1

SEC filer profile

How Tesaro is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARTESARO, Inc.2
  • CIK0001491576
  • Employer ID (EIN)27-22496872
  • Filer statusLarge accelerated filer2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • Business address1000 Winter Street, Suite 3300, Waltham, MA 024512
  • Phone(339) 970-09002
  • Shares outstanding55,046,956 as of Oct 29, 201832
  • Public float$5.2B as of Jun 30, 20178
  • On EDGAR sinceMay 20, 20102
  • Filings554 in all: 4 (234), 8-K (88), SC 13G/A (35), 3 (34), 10-Q (20), CT ORDER (12), SC 13G (11), 424B5 (10)2
    All 42 form types

    CORRESP (10), SC 13D/A (9), SC 14D9/A (7), SC TO-T/A (7), 10-K (6), DEF 14A (6), S-1/A (6), S-8 (6), S-8 POS (6), 4/A (4), D (4), UPLOAD (4), 424B4 (3), 8-K/A (3), FWP (3), SC 13D (3), EFFECT (2), S-1 (2), S-3ASR (2), SC TO-C (2), SC14D9C (2), 10-Q/A (1), 15-12B (1), 25-NSE (1), 305B2 (1), 424B1 (1), 424B7 (1), 8-A12B (1), CERTNAS (1), DEFA14A (1), POSASR (1), S-1MEF (1), SC 14D9 (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Feb 28, 2018
    Quarterly report (10-Q) Nov 2, 2018
    Proxy statement (DEF 14A) Apr 6, 2018
    Latest 8-K (8-K) Jan 24, 2019

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32